...
首页> 外文期刊>Theranostics >Near-Infrared Light Triggered ROS-activated Theranostic Platform based on Ce6-CPT-UCNPs for Simultaneous Fluorescence Imaging and Chemo-Photodynamic Combined Therapy
【24h】

Near-Infrared Light Triggered ROS-activated Theranostic Platform based on Ce6-CPT-UCNPs for Simultaneous Fluorescence Imaging and Chemo-Photodynamic Combined Therapy

机译:基于CE6-CPT-UCNP的近红外光触发ROS激活的Theranostic平台,同时荧光成像和化学光动力组合治疗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Many drug controlled release methods have been integrated in multifunctional nanoparticles, such as pH-, redox-, temperature-, enzyme-, and light-responsive release. However, few report is associated with the ROS responsive drug controlled release. Herein, a thioketal linker-based ROS responsive drug (camptothecin conjugated with thioketal linker, abbreviated as TL-CPT) was prepared and the thioketal linker could be cleaved by ROS(reactive oxygen species). To achieve cancer simultaneous optical imaging, photodynamic therapy and chemotherapy, the photosensitizer Chlorin e6(Ce6), TL-CPT and carboxyl-mPEG were loaded on the upconversion nanoparticles (UCNPs), which were named as Ce6-CPT-UCNPs. Under 980 nm laser irradiation, Ce6-CPT-UCNPs emitted a narrow emission band at 645-675 nm which was overlapped with Ce6 absorption peak. Ce6 absorbed the light to produce ROS, which was used for photodynamic therapy and to cleave the thioketal linker in Ce6-CPT-UCNPs to release camptothecin for chemotherapy. Meanwhile, Ce6 absorbed the light, was used for near-infrared fluorescence imaging. The in vivo biodistribution studies showed that the prepared nanoparticles had high orthotopic lung cancer targeting efficiency. The in vivo therapeutic results demonstrated that NCI-H460 lung cancers could be completely eliminated by combining chemo- and photodynamic therapy under 980 nm laser irradiation. The prepared multifunctional Ce6-CPT-UCNPs have great potential in applications such as cancer targeted fluorescent imaging, simultaneous ROS activated chemo- and photodynamic therapy in near future.
机译:许多药物控释方法已在多官能纳米颗粒中集成在多官能纳米颗粒中,例如pH-,氧化还原,温度,酶和轻响应释放。但是,很少有报告与ROS响应药物控制释放有关。在此,制备了一种基于硫内脏连接基的ROS响应药物(与致琼脂连接物缀合,缩写为TL-CPT),并且可以通过ROS(反应性氧物质)裂解硫桶仪连接物。为了实现癌症同步光学成像,光动力治疗和化疗,将光敏剂氯E6(CE6),TL-CPT和羧基-MPEG加载到上转换纳米颗粒(UCNP)上,其被命名为CE6-CPT-UCNPS。在980nm激光照射下,CE6-CPT-UCNP在645-675nm下发射窄发射带,其与CE6吸收峰重叠。 CE6吸收光以产生ROS,用于光动力学治疗,并切割CE6-CPT-UCNP中的硫内脏接头,从而释放CAMPTOTHENIN用于化疗。同时,CE6吸收光,用于近红外荧光成像。体内生物分布研究表明,制备的纳米颗粒具有高表现肺癌的靶向效率。体内治疗结果表明,通过在980nm激光照射下结合化学和光动力治疗,可以完全消除NCI-H460肺癌。制备的多功能CE6-CPT-UCNPS在癌症靶向荧光成像,同时ROS活化的化学和光动力治疗等应用中具有很大的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号